# Imunon (IMNN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IMNN
## Company Profile
- Ticker: IMNN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology, Infectious Disease
## Stock Data
- Close: 1.08 USD
- Market cap: 8992532.520000001 USD
- Last updated: 2026-10-09
## Business Overview
### DNA-Mediated Immunotherapy Company
IMUNON develops localized gene-based immunotherapies for cancer.
### IMNN-001
IMNN-001 is a DNA plasmid encoding interleukin-12 delivered into the peritoneal cavity to stimulate antitumor immunity in advanced ovarian cancer.
### OVATION Program
The Phase 3 OVATION 3 study adds IMNN-001 to frontline chemotherapy after Phase 2 results suggested an overall-survival benefit.
## Why The Stock Is Moving

Following the latest company update, “IMUNON to Participate in Upcoming Investor Conferences”, IMNN closed down 6.14% at $1.07 on Oct 8, 2026. The move occurred in the trading session associated with this company update.

## Future Catalysts

- Enrollment in the Phase 3 OVATION 3 study is expected to complete by the first quarter of 2029.

## Recent News
- 2026-10-08 13:00 EST — [IMUNON to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/IMNN/imunon-to-participate-in-upcoming-investor-conferences-94108503) — Source: Imunon
- 2026-09-29 12:00 EST — [IMUNON Converts $1.2 Million of Debt-to-Equity](https://biopharmsignal.com/news/IMNN/imunon-converts-1-2-million-of-debt-to-equity-687dc896) — Source: Imunon
- 2026-09-24 12:05 EST — [IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan](https://biopharmsignal.com/news/IMNN/imunon-makes-the-frontline-case-for-phase-3-imnn-001-study-14-7-month-os-signal--e9961969) — Source: Imunon
- 2026-09-22 12:05 EST — [IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review](https://biopharmsignal.com/news/IMNN/imunon-reports-independent-data-monitoring-committee-recommends-continued-phase--2a92e111) — Source: Imunon
- 2026-09-10 13:30 EST — [IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001](https://biopharmsignal.com/news/IMNN/imunon-enters-cooperative-research-and-development-agreement-with-national-cance-44c5d934) — Source: Imunon